NEW ORLEANS — At 3 years, patients with severe aortic stenosis at low surgical risk who had transcatheter aortic valve replacement with a self-expanding valve continued to have lower risk for death or stroke than those who had surgical AVR. In the main results of the Evolut Low Risk Trial, risk for all-cause mortality or disabling stroke at 2 years was numerically lower and noninferior in